$TCBP News clips EDINBURGH, Scotland, March 17, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announces orphan drug status has been granted for lead product OmnImmune® for use in Acute Myeloid Leukemia ("AML"). After reviewing the Phase 1b/2a trial results in relapse/refractory AML patients the FDA approved the Company's application for Orphan Drug Status.